Bengaluru: Aurobindo Pharma Ltd, India’s second-largest drugmaker by market capitalisation, posted a 21.7% fall in its second-quarter profit on Monday, hurt by higher expenses, but beat analysts’ estimates.

Net profit was Rs611 crore ($83.81 million) in the quarter ended 30 September, compared with Rs781 crore a year earlier, the company said.

Analysts on average had expected a profit of Rs606 crore, according to IBES data from Refinitiv.

Total expenses rose 14.3% to Rs3,964 crore, while income from operations climbed 7.19% to Rs4,667 crore.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed)